Associations between COX-2 polymorphisms, blood cholesterol and risk of acute coronary syndrome

Atherosclerosis

Volumn 209, Issue 1, 2010, Pages 155-162

  Vogel, Ulla ^a,b,c   Segel, Stine ^d   Dethlefsen, Claus ^d   Tjønneland, Anne ^e   Saber, Anne Thoustrup ^c   Wallin, Håkan ^c   Jensen, Majken K ^d,f   Schmidt, Erik B ^d   Andersen, Paal Skytt ^g   Overvad, Kim ^d,f  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b ROSKILDE UNIVERSITY   (Denmark)

^c NATIONAL RESEARCH CENTRE FOR THE WORKING ENVIRONMENT   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g STATENS SERUM INSTITUT   (Denmark)

Author keywords

Alcohol; Gene environment interactions; NSAID; Prospective study; PTGS2

Indexed keywords

ALCOHOL; CHOLESTEROL; CYCLOOXYGENASE 2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG USE; FEMALE; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING; WILD TYPE;

ACUTE CORONARY SYNDROME; ALCOHOL DRINKING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHOLESTEROL; CYCLOOXYGENASE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SEX FACTORS; SMOKING;

EID: 77049123443     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.08.036     Document Type: Article

References (37)

1. Krotz F., Schiele T.M., Klauss V., and Sohn H.Y. Selective COX-2 inhibitors and risk of myocardial infarction. J Vasc Res 42 (2005) 312-324
2. Sanak M., Szczeklik W., and Szczeklik A. Association of COX-2 gene haplotypes with prostaglandins production in bronchial asthma. J Allergy Clin Immunol 116 (2005) 221-223
3. Zhang X., Miao X., Tan W., et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 129 (2005) 565-576
4. Martey C.A., Pollock S.J., Turner C.K., et al. Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. Am J Physiol Lung Cell Mol Physiol 287 (2004) L981-L991
5. Mustonen H., Hietaranta A., Puolakkainen P., et al. Ethanol induced NF-{kappa}B activation protects against cell injury in cultured rat gastric mucosal epithelium. Am J Physiol Gastrointest Liver Physiol 292 (2007) G1614-G1621
6. Tipoe G.L., Liong E.C., Casey C.A., et al. A voluntary oral ethanol-feeding rat model associated with necroinflammatory liver injury. Alcohol Clin Exp Res 32 (2008) 669-682
7. Yuan C.J., Mandal A.K., Zhang Z., and Mukherjee A.B. Transcriptional regulation of cyclooxygenase-2 gene expression: novel effects of nonsteroidal anti-inflammatory drugs. Cancer Res 60 (2000) 1084-1091
8. Ramsay R.G., Friend A., Vizantios Y., et al. Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB. Cancer Res 60 (2000) 1805-1809
9. Chan E.S., Zhang H., Fernandez P., et al. Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk. Arthritis Res Ther 9 (2007) R4
10. Narasimha A., Watanabe J., Lin J.A., et al. A novel anti-atherogenic role for COX-2-potential mechanism for the cardiovascular side effects of COX-2 inhibitors. Prostaglandins Other Lipid Mediat 84 (2007) 24-33
11. Tjonneland A., Olsen A., Boll K., et al. Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark. Scand J Public Health 35 (2007) 432-441
12. Barlow W.E., Ichikawa L., Rosner D., and Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 52 (1999) 1165-1172
13. Joensen A.M., Jensen M.K., Overvad K., et al. Predictive values of acute coronary syndrome discharge diagnoses differed in the Danish National Patient Registry. J Clin Epidemiol 62 (2009) 188-194
14. Jensen M.K., Rimm E.B., Rader D., et al. S447X variant of the lipoprotein lipase gene, lipids, and risk of coronary heart disease in 3 prospective cohort studies. Am Heart J 157 (2009) 384-390
15. Jensen M.K., Rimm E.B., Mukamal K.J., et al. The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations. Eur Heart J 30 (2009) 1584-1589
16. Vogel U., Segel S., Dethlefsen C., et al. PPARgamma Pro12Ala polymorphism and risk of acute coronary syndrome in a prospective study of Danes. BMC Med Genet 10 (2009) 52
17. Tolstrup J.S., Jensen M.K., Tjonneland A., Overvad K., and Gronbaek M. Drinking pattern and mortality in middle-aged men and women. Addiction 99 (2004) 323-330
18. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 (1988) 1215
19. Vogel U., Christensen J., Wallin H., et al. Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res 617 (2007) 138-146
20. Campa D., Zienolddiny S., Maggini V., et al. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 25 (2004) 229-235
21. Kalbfleisch J.D., and Lawless J.F. Likelihood analysis of multi-state models for disease incidence and mortality. Stat Med 7 (1988) 149-160
22. Vogel U., Christensen J., Wallin H., et al. Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res 639 (2008) 89-100
23. Vogel U., Christensen J., Dybdahl M., et al. Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res 624 (2007) 88-100
24. Hansen R.D., Sorensen M., Tjonneland A., et al. XPA A23G, XPC Lys939Gln, XPD Lys751Gln and XPD Asp312Asn polymorphisms, interactions with smoking, alcohol and dietary factors, and risk of colorectal cancer. Mutat Res 619 (2007) 68-80
25. Hansen R.D., Sorensen M., Tjonneland A., et al. A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study. BMC Cancer 8 (2008) 54
26. Hansen R.D., Krath B.N., Frederiksen K., et al. GPX1 Pro(198)Leu polymorphism, erythrocyte GPX activity, interaction with alcohol consumption and smoking, and risk of colorectal cancer. Mutat Res 664 (2009) 13-19
27. Raaschou-Nielsen O., Sorensen M., Hansen R.D., et al. GPX1 Pro198Leu polymorphism, interactions with smoking and alcohol consumption, and risk for lung cancer. Cancer Lett 247 (2007) 293-300
28. Vogel U., Sorensen M., Hansen R.D., et al. Gene-environment interactions between smoking and a haplotype of RAI, ASE-1 and ERCC1 polymorphisms among women in relation to risk of lung cancer in a population-based study. Cancer Lett 247 (2007) 159-165
29. Perneger T.V. What's wrong with Bonferroni adjustments. BMJ 316 (1998) 1236-1238
30. Bonaterra G.A., Hildebrandt W., Bodens A., et al. Increased cyclooxygenase-2 expression in peripheral blood mononuclear cells of smokers and hyperlipidemic subjects. Free Radic Biol Med 38 (2005) 235-242
31. Vinals M., Martinez-Gonzalez J., Badimon J.J., and Badimon L. HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2). Arterioscler Thromb Vasc Biol 17 (1997) 3481-3488
32. Szczeklik W., Sanak M., Rostoff P., et al. Common polymorphisms of cyclooxygenase-2 and prostaglandin E2 receptor and increased risk for acute coronary syndrome in coronary artery disease. Thromb Haemost 100 (2008) 893-898
33. Cipollone F., Toniato E., Martinotti S., et al. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 291 (2004) 2221-2228
34. Lee C.R., North K.E., Bray M.S., et al. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther 83 (2008) 52-60
35. Kohsaka S., Volcik K.A., Folsom A.R., et al. Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis 196 (2008) 926-930
36. Chang L.W., Chang Y.C., Ho C.C., Tsai M.H., and Lin P. Increase of carcinogenic risk via enhancement of cyclooxygenase-2 expression and hydroxyestradiol accumulation in human lung cells as a result of interaction between BaP and 17-beta estradiol. Carcinogenesis 28 (2007) 1606-1612
37. Norata G.D., Tibolla G., Seccomandi P.M., Poletti A., and Catapano A.L. Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells. J Clin Endocrinol Metab 91 (2006) 546-554